Aura Biosciences, Inc.
NASDAQ:AURA
9.69 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 2.056 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.313 | 0.306 | 0.324 | 0.4 | 0.3 | 0.328 | 0.323 | 0.302 | 0.296 | 0.256 | 0.23 | 0.218 | 0.2 | 0.268 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.313 | -0.306 | 1.732 | -0.4 | -0.3 | -0.328 | -0.323 | -0.302 | -0.296 | -0.256 | -0.23 | -0.218 | -0.2 | -0.268 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.842 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 16.879 | 17.052 | 20.28 | 15.428 | 15.12 | 14.405 | 13.159 | 11.293 | 9.51 | 8.276 | 7.979 | 6.365 | 6.632 | 4.185 | 3.543 | 2.85 | 5.314 | 6.335 |
| General & Administrative Expenses
| 5.883 | 5.261 | 4.503 | 5.06 | 5.156 | 5.039 | 4.454 | 4.762 | 4.306 | 4.535 | 3.648 | 2.53 | 2.169 | 1.742 | 1.366 | 0.781 | 0.841 | 1.176 |
| Selling & Marketing Expenses
| -0.313 | -0.306 | -0.324 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.57 | 4.955 | 4.179 | 5.06 | 5.156 | 5.039 | 4.454 | 4.762 | 4.306 | 4.535 | 3.648 | 2.53 | 2.169 | 1.742 | 1.366 | 0.781 | 0.841 | 1.176 |
| Other Expenses
| -0.026 | -0.032 | -0.026 | -0.005 | -0.032 | -0.013 | -0.008 | -0.007 | -0.005 | 0 | 0 | 0.052 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 22.449 | 22.007 | 24.459 | 20.488 | 20.276 | 19.444 | 17.613 | 16.055 | 13.816 | 12.811 | 11.627 | 8.895 | 8.801 | 5.927 | 4.909 | 3.631 | 6.155 | 7.511 |
| Operating Income
| -22.762 | -22.313 | -24.783 | -18.512 | -20.276 | -19.444 | -17.613 | -16.055 | -13.816 | -12.811 | -11.627 | -8.895 | -8.801 | -5.927 | -4.909 | -3.631 | -6.155 | -7.511 |
| Operating Income Ratio
| 0 | 0 | -12.054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.425 | 2.653 | 2.789 | -0.005 | -0.032 | 1.978 | 1.054 | 0.154 | 0.056 | -0.024 | -0.012 | 0.052 | -0.055 | 0.001 | 0.002 | 0 | -0.001 | -0.001 |
| Income Before Tax
| -20.337 | -19.66 | -21.994 | -18.512 | -18.299 | -17.466 | -16.559 | -15.901 | -13.468 | -12.835 | -11.634 | -8.838 | -8.852 | -5.927 | -4.907 | -3.631 | -6.156 | -7.512 |
| Income Before Tax Ratio
| 0 | 0 | -10.697 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.046 | 0.137 | -0.348 | -2.009 | -2.306 | 25.249 | -0.154 | -0.353 | 0.024 | -0.223 | -0.057 | 0.051 | -0.083 | 0 | 0 | 1.927 | 1.927 |
| Net Income
| -20.337 | -19.706 | -22.131 | -18.512 | -18.299 | -15.16 | -41.808 | -15.747 | -13.468 | -12.859 | -11.634 | -8.838 | -8.852 | -5.927 | -4.907 | -3.631 | -8.083 | -9.439 |
| Net Income Ratio
| 0 | 0 | -10.764 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.41 | -0.4 | -0.5 | -0.48 | -0.48 | -0.4 | -1.31 | -0.54 | -0.46 | -0.44 | -0.42 | -0.32 | -0.45 | -0.3 | -0.25 | -0.19 | -22.15 | -27.28 |
| EPS Diluted
| -0.41 | -0.4 | -0.5 | -0.48 | -0.48 | -0.4 | -1.31 | -0.54 | -0.46 | -0.44 | -0.42 | -0.32 | -0.45 | -0.3 | -0.25 | -0.19 | -22.13 | -27.27 |
| EBITDA
| -22.449 | -22.007 | -24.459 | -18.512 | -19.976 | -19.444 | -17.29 | -15.431 | -13.581 | -12.506 | -11.615 | -8.731 | -8.546 | -5.743 | -4.683 | -3.399 | -5.964 | -7.329 |
| EBITDA Ratio
| 0 | 0 | -11.896 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |